^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta)

    i
    Other names: CAMK2D, Calcium/Calmodulin Dependent Protein Kinase II Delta, Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Delta, Calcium/Calmodulin-Dependent Protein Kinase (CaM Kinase) II Delta, CAMKD, Calcium/Calmodulin-Dependent Protein Kinase Type II Delta Chain, CaM Kinase II Delta Subunit, CaM Kinase II Subunit Delta, CaM-Kinase II Delta Chain, CaMK-II Delta Subunit, CaMK-II Subunit Delta
    2ms
    Targeting CaMKIIδ Overcomes Therapy Resistance in Acute Myeloid Leukemia by Suppressing STAT3/CDK6/BCL-2 Survival Axis. (PubMed, J Leukoc Biol)
    Strikingly, pharmacological blockade of CaMKIIδ using the small-molecule inhibitor hesperadin effectively eliminates AML cells in vitro and achieves sustained disease regression in AML xenograft mouse models. Our findings establish CaMKIIδ as a central regulator of AML cell survival and apoptosis, providing a preclinical rationale for targeting CaMKIIδ to overcome therapy resistance in AML.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CDK6 (Cyclin-dependent kinase 6) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta)
    3ms
    Integrative phosphoproteomic network analysis identifies CAMK2D as a shared regulator of TPD52 family proteins in cancer. (PubMed, Protoplasma)
    Notably, hypophosphorylation at TPD52_S171/S176 was observed in hepatocellular and lung carcinomas, whereas hyperphosphorylation at TPD52L2_S166 prevailed in ovarian and pancreatic cancers, underscoring biomarker utility. Phosphorylation-driven interactomes emphasized roles in vesicular trafficking and oncogenesis This study catalogues the phosphorylation events and explores the potential of TPD52 family as a phosphoregulated hub in cancer biology, with CAMK2D as a potential therapeutic target.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • TPD52L1 (Tumor protein D53)
    3ms
    Recombination between fragile regions associated with chromosomal rearrangements in glioblastoma can be mediated by RAGs. (PubMed, iScience)
    Finally, we recapitulate the glioblastoma associated AMY1B and RN7SKP123-MTF2 chromosomal rearrangement using an extrachromosomal assay. Thus, the present study provides mechanistic insights into the generation of chromosomal aberrations associated with glioblastoma.
    Journal
    |
    CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • IRX5 (Iroquois Homeobox 5) • RAG1 (Recombination Activating 1)
    3ms
    Reactivating necroptosis in colorectal cancer potentiates chemotherapy and antitumor immune responses. (PubMed, Cancer Lett)
    OSW-1 displayed strong synergy with 5-fluorouracil (5-FU), effectively eliminating RIP3-silenced CRC cells and tumors through the induction of both necroptosis and apoptosis...Furthermore, the combination increased immune infiltration in patient-derived primary CRC Air-Liquid Interface (ALI) organoid cultures with autologous immune tumor microenvironment. Collectively, our findings support a novel strategy to activate RIP3-independent necroptosis, providing a compelling rationale to boost the efficacy of chemotherapy via enhanced CRC cell killing and antitumor immunity.
    Journal
    |
    CD8 (cluster of differentiation 8) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta)
    |
    5-fluorouracil
    3ms
    Glioma angiogenesis phosphoproteome landscape and biomarker sets identified with phenome-centered multiomics toward 3P medical approaches. (PubMed, EPMA J)
    These findings provide concrete molecular targets for antiangiogenic therapy and establish clinically actionable biomarkers for glioma patient stratification in the 3PM framework. The online version contains supplementary material available at 10.1007/s13167-025-00428-1.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • HSPB1 (Heat shock 27kDa protein 1) • L1CAM (L1 cell adhesion molecule) • PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha) • MYLK (Myosin Light Chain Kinase) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1) • PRKAR2B (Protein Kinase CAMP-Dependent Type II Regulatory Subunit Beta)
    5ms
    Identification of novel gene fusions in high-grade serous ovarian carcinoma: implications for tumorigenesis and targeted therapy. (PubMed, Cancer Genet)
    This study identified candidate driver fusion genes and suggested new therapeutic targets for HGSOCs.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • AXL (AXL Receptor Tyrosine Kinase) • HDAC1 (Histone Deacetylase 1) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • LATS1 (Large Tumor Suppressor Kinase 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • CAMKK1 (Calcium/Calmodulin Dependent Protein Kinase Kinase 1) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1) • SH3PXD2A (SH3 And PX Domains 2A) • YY1 (YY1 Transcription Factor) • ZNF143 (Zinc Finger Protein 143)
    |
    TP53 mutation
    7ms
    Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents. (PubMed, Nat Commun)
    RBFOX1 loss reverts cardiomyocytes to a less mature state with open chromatin and susceptibility to DNA damage, apoptosis or CIC, when treated with DNA intercalating or alkylating anticancer agents. These findings suggest cumulative inosine and hypoxanthine levels may be a biomarker predicting patient susceptibility to DNA damaging anti-cancer agents.
    Journal
    |
    ADORA2A (Adenosine A2a Receptor) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta)
    10ms
    Depletion of oxysterol-binding proteins by OSW-1 triggers RIP1/RIP3-independent necroptosis and sensitization to cancer immunotherapy. (PubMed, Cell Death Differ)
    Furthermore, OSW-1-induced necroptosis is highly immunogenic and sensitizes syngeneic colorectal tumors to anti-PD-1 immunotherapy. Together, our results identified a novel RIP1/RIP3-independent necroptosis pathway underlying the extremely potent anticancer activity of OSW-1, which can be harnessed to develop new anticancer therapies by selectively stimulating antitumor immunity.
    Journal
    |
    CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
    1year
    Discovery of myeloid zinc finger (MZF) 1 nuclear bodies. (PubMed, Biochem Biophys Res Commun)
    Sumoylated MZF1 can interact with proteins containing SUMO-interaction motifs (SIM) through SUMO-SIM interaction. Interactome analysis revealed that its NBs participate in the stress response (TPR and UBAP2L), protein folding (CALR and ANKRD40), transcription, post-translational modification (TRIM33, ACOT7, CAMK2D, and CAMK2G), and RNA binding (ALURBP and CPSF5).
    Journal
    |
    TRIM33 (Tripartite Motif Containing 33) • CALR (Calreticulin) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • MZF1 (Myeloid Zinc Finger 1)
    1year
    CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma. (PubMed, Adv Sci (Weinh))
    This study also evaluates Tetrandrine (TET), a small molecule compound, as a potent CAMKIIδ inhibitor...Collectively, this study highlights how CAMKIIδ is critical in BCL progression. The results also pave the way for innovative therapeutic strategies for treating aggressive BCL.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • IRF4 (Interferon regulatory factor 4) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta)
    |
    CBT-1 (tetrandrine)
    1year
    Mechanism and function of CEACAM1 splice isoforms. (PubMed, Eur J Clin Invest)
    More pre-clinical and clinical studies are needed to elucidate the precise mechanisms by which CEACAM1 RNA splicing may be exploited to develop targeted interventions towards novel therapeutic strategies.
    Review • Journal • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    over1year
    Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles. (PubMed, J Vis Exp)
    Ecklonia kurome Okam (Kunbu) and Herba Ephedrae (Mahuang) were identified, and the effects of the active ingredients on AD were displayed. Finally, enrichment analysis of Kunbu and Mahuang suggested that they might act as therapeutic candidates for gender specificity of AD.
    Journal
    |
    GNAS (GNAS Complex Locus) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • APOE (Apolipoprotein E) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • CALM2 (Calmodulin 2)